David Borsook ● Lino Beccera
Edward Bullmore ● Richard Hargreaves
Editors

2009

Implications for Disease and Therapy

The last decade has seen a loss of confidence in the big pharma model for the development of new drugs. Despite unprecedented development costs, only about 10% of molecules entering Phase I were registered as drugs between 1991 and 2000 (Kola and Landis 2004). More concerning for the industry is that a significant proportion of the molecules failed in late phase development, after major investments already had been made.